PT - JOURNAL ARTICLE AU - Krishnamurthy, Hari Krishnan AU - Jayaraman, Vasanth AU - Krishna, Karthik AU - Wang, Tianhao AU - Bei, Kang AU - Suresh, Chithra AU - Matilda, Shiny AU - Rai, Alex J AU - Welc-Falęciak, Renata AU - Pawełczyk, Agnieszka AU - Blanton, Lucas S. AU - Chrdle, Aleš AU - Fořtová, Andrea AU - Růžek, Daniel AU - Nasrallah, Gheyath K. AU - Abu-Raddadi, Laith J. AU - Al-Sadeq, Duaa W. AU - Abdallah, Marah Abed Alhakim AU - Lilleri, Daniele AU - Fornara, Chiara AU - D’Angelo, Piera AU - Furione, Milena AU - Venermo, Maria Söderlund- AU - Hedman, Klaus AU - Chochlakis, Dimosthenis AU - Psaroulaki, Anna AU - Makridaki, Eirini AU - Ntoula, Artemis AU - Rajasekaran, John J. TI - A customizable multiplex protein microarray for antibody testing and its application for tick-borne and other infectious diseases AID - 10.1101/2023.10.06.23296637 DP - 2023 Jan 01 TA - medRxiv PG - 2023.10.06.23296637 4099 - http://medrxiv.org/content/early/2023/10/12/2023.10.06.23296637.short 4100 - http://medrxiv.org/content/early/2023/10/12/2023.10.06.23296637.full AB - Tick-borne infections are the most common vector-borne diseases in the USA. Ticks harbor and spread several infections with Lyme disease being the most common tickborne infection in the US and Europe. Lack of awareness about tick populations, specific diagnostic tests, and overlapping symptoms of tick-borne infections can often lead to misdiagnosis affecting treatment and the prevalence data reported especially for non-Lyme tick-borne infections. The diagnostic tests currently available for tick-borne diseases are severely limited in their ability to provide accurate results and cannot detect multiple pathogens in a single run. The multiplex protein microarray developed at Vibrant was designed to detect multiple serological antibodies thereby detecting exposure to multiple pathogens simultaneously. Our microarray in its present form can accommodate 400 antigens and can multiplex across antigen types, whole cell sonicates, recombinant proteins, and peptides. A designed array containing multiple antigens of several microbes including Borrelia burgdorferi, the Lyme disease spirochete, was manufactured and evaluated. The immunoglobulin M (IgM) and G (IgG) responses against several tick-borne microbes and other infectious agents were analyzed for analytical and clinical performance. The microarray improved IgM and IgG sensitivities and specificities of individual microbes when compared with the respective gold standards. The testing was also performed in a single run in comparison to multiple runs needed for comparable testing standards. In summary, our study presents a flexible multiplex microarray platform that can provide quick results with high sensitivity and specificity for evaluating exposure to varied infectious agents especially tick-borne infections.Competing Interest StatementThe authors have read the journal's policy and the authors of this manuscript have the following competing interests. CS and SM are paid employees of Vibrant America LLC. KK, VJ, TW, KB, HKK, and JJR are paid employees of Vibrant Sciences LLC. he other authors are academic collaborators who provided samples and assisted in the review and editing of the manuscript. AJR is a paid consultant of Vibrant America LLC. Vibrant America offers commercial testing for Lyme disease and other infectious diseases and could benefit from increased testing.Funding StatementVibrant America provided funding for this study in the form of salaries for authors [CS, SM, KK, VJ, TW, KB, HKK, JJR]. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Internal Review Board (AKBE/24/16) of the Warsaw Medical University gave approval for this work. WCG IRB #1-1574995-1 of WCGIRB waived ethical approval for this work. Schulman IRB # 201700960, #201607925 of Schulman IRB gave ethical approval for this work. 17-00013 (WCMC-Q) and QU-IRB 518-EA/15 of Qatar University gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used to support the findings of this study can be acquired from Vibrant America LLC